炎症小体和细胞焦亡作为 COVID-19 的治疗靶点。
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.
机构信息
School of Postgraduate Studies, International Medical University, 57000 Kuala Lumpur, Malaysia.
Department of Immunobiology, Yale University School of Medicine, New Haven, CT 06520.
出版信息
J Immunol. 2020 Jul 15;205(2):307-312. doi: 10.4049/jimmunol.2000513. Epub 2020 Jun 3.
Abstract
The inflammatory response to severe acute respiratory syndrome-related coronavirus 2 infection has a direct impact on the clinical outcomes of coronavirus disease 2019 patients. Of the many innate immune pathways that are engaged by severe acute respiratory syndrome-related coronavirus 2, we highlight the importance of the inflammasome pathway. We discuss available pharmaceutical agents that target a critical component of inflammasome activation, signaling leading to cellular pyroptosis, and the downstream cytokines as a promising target for the treatment of severe coronavirus disease 2019-associated diseases.
摘要
严重急性呼吸综合征相关冠状病毒 2 感染引起的炎症反应对 2019 年冠状病毒病患者的临床结局有直接影响。在严重急性呼吸综合征相关冠状病毒 2 激活的许多先天免疫途径中，我们强调了炎症小体途径的重要性。我们讨论了现有的靶向炎症小体激活的关键组成部分、导致细胞细胞焦亡的信号传导以及下游细胞因子的药物，它们是治疗严重 2019 年冠状病毒病相关疾病的有希望的靶点。
相似文献
1
Inflammasomes and Pyroptosis as Therapeutic Targets for COVID-19.炎症小体和细胞焦亡作为 COVID-19 的治疗靶点。
J Immunol. 2020 Jul 15;205(2):307-312. doi: 10.4049/jimmunol.2000513. Epub 2020 Jun 3.
2
Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity.通过对固有免疫的控制调节来预防和治疗 COVID-19 疾病。
Eur J Immunol. 2020 Jul;50(7):932-938. doi: 10.1002/eji.202048693. Epub 2020 Jun 15.
3
Innate Immune Signaling and Proteolytic Pathways in the Resolution or Exacerbation of SARS-CoV-2 in Covid-19: Key Therapeutic Targets?固有免疫信号和蛋白水解途径在新冠病毒 2 型（SARS-CoV-2）引起的新冠肺炎（Covid-19）中的转归或恶化：关键治疗靶点？
Front Immunol. 2020 May 28;11:1229. doi: 10.3389/fimmu.2020.01229. eCollection 2020.
4
Targeting the NLRP3 Inflammasome in Severe COVID-19.针对严重 COVID-19 的 NLRP3 炎性小体。
Front Immunol. 2020 Jun 23;11:1518. doi: 10.3389/fimmu.2020.01518. eCollection 2020.
5
Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.I 型和 III 型干扰素 - 诱导、信号转导、逃逸及其在抗击 COVID-19 中的应用。
Cell Host Microbe. 2020 Jun 10;27(6):870-878. doi: 10.1016/j.chom.2020.05.008. Epub 2020 May 27.
6
Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19.新型冠状病毒诱导的NLRP3炎性小体激活：治疗COVID-19的潜在药物靶点
Front Immunol. 2020 May 19;11:1021. doi: 10.3389/fimmu.2020.01021. eCollection 2020.
7
Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.训练免疫：降低 SARS-CoV-2 感染易感性和严重程度的工具。
Cell. 2020 May 28;181(5):969-977. doi: 10.1016/j.cell.2020.04.042. Epub 2020 May 4.
8
Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.利用免疫系统克服 COVID-19 中的细胞因子风暴并降低病毒载量：疾病各阶段和治疗药物综述。
Virol J. 2020 Oct 15;17(1):154. doi: 10.1186/s12985-020-01415-w.
9
SARS-CoV-2: characteristics and current advances in research.SARS-CoV-2：特性及研究进展。
Virol J. 2020 Jul 29;17(1):117. doi: 10.1186/s12985-020-01369-z.
10
Differential immune activation profile of SARS-CoV-2 and SARS-CoV infection in human lung and intestinal cells: Implications for treatment with IFN-β and IFN inducer.SARS-CoV-2 和 SARS-CoV 感染人肺和肠道细胞的免疫激活特征差异：使用 IFN-β 和 IFN 诱导剂治疗的意义。
J Infect. 2020 Oct;81(4):e1-e10. doi: 10.1016/j.jinf.2020.07.016. Epub 2020 Jul 21.
引用本文的文献
1
The prognostic values of monitoring changes in coagulative, inflammatory, and blood chemistry markers in COVID-19 patient's before and during admission to ICU: a retrospective cohort study.监测COVID-19患者在入住重症监护病房前后凝血、炎症和血液化学标志物变化的预后价值：一项回顾性队列研究。
Ann Med Surg (Lond). 2025 Jul 22;87(9):5401-5408. doi: 10.1097/MS9.0000000000003600. eCollection 2025 Sep.
2
Murine Cytomegalovirus and Human Cytomegalovirus Differ in Pyroptosis Induction in Different Cell Types During Productive Replication.小鼠巨细胞病毒和人巨细胞病毒在生产性复制过程中对不同细胞类型焦亡诱导作用存在差异。
Viruses. 2025 Aug 12;17(8):1106. doi: 10.3390/v17081106.
3
The roles of macrophages and monocytes in COVID-19 Severe Respiratory Syndrome.巨噬细胞和单核细胞在新型冠状病毒肺炎严重呼吸综合征中的作用。
Cell Insight. 2025 May 8;4(4):100250. doi: 10.1016/j.cellin.2025.100250. eCollection 2025 Aug.
4
Investigation of the effect of serum gasdermin d levels on clinical course and mortality in patients with covid-19.血清Gasdermin D水平对新型冠状病毒肺炎患者临床病程及死亡率影响的研究
BMC Infect Dis. 2025 Jul 3;25(1):893. doi: 10.1186/s12879-025-11277-8.
5
Inhibiting NINJ1-dependent plasma membrane rupture protects against inflammasome-induced blood coagulation and inflammation.抑制NINJ1依赖性质膜破裂可预防炎性小体诱导的血液凝固和炎症。
Elife. 2025 Mar 17;12:RP91329. doi: 10.7554/eLife.91329.
6
SARS-CoV-2-ORF-3a Mediates Apoptosis Through Mitochondrial Dysfunction Modulated by the K Ion Channel.严重急性呼吸综合征冠状病毒2开放阅读框3a通过钾离子通道调节的线粒体功能障碍介导细胞凋亡。
Int J Mol Sci. 2025 Feb 13;26(4):1575. doi: 10.3390/ijms26041575.
7
Unveiling the Impact of COVID-19 on Ovarian Function and Premature Ovarian Insufficiency: A Systematic Review.揭示2019冠状病毒病对卵巢功能和卵巢早衰的影响：一项系统综述
Biomedicines. 2025 Feb 7;13(2):407. doi: 10.3390/biomedicines13020407.
8
Haematological Manifestations of SARS-CoV-2: Insights into Erythropoiesis, Hepcidin Regulation, and Cytokine Storm.新型冠状病毒肺炎的血液学表现：对红细胞生成、铁调素调节及细胞因子风暴的见解
Int J Mol Sci. 2025 Jan 21;26(3):874. doi: 10.3390/ijms26030874.
9
The relationship between microRNAs and COVID-19 complications.微小RNA与新型冠状病毒肺炎并发症之间的关系。
Noncoding RNA Res. 2024 Aug 22;10:16-24. doi: 10.1016/j.ncrna.2024.08.007. eCollection 2025 Feb.
10
The interplay of transition metals in ferroptosis and pyroptosis.过渡金属在铁死亡和细胞焦亡中的相互作用。
Cell Div. 2024 Aug 3;19(1):24. doi: 10.1186/s13008-024-00127-9.
本文引用的文献
1
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.I 型干扰素易感性区分 SARS-CoV-2 和 SARS-CoV。
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
2
Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study.乳酸脱氢酶，重症新型冠状病毒肺炎患者的独立危险因素：一项回顾性观察研究
Aging (Albany NY). 2020 Jun 24;12(12):11245-11258. doi: 10.18632/aging.103372.
3
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation.美国食品药品监督管理局批准的双硫仑通过阻断gasdermin D 孔形成来抑制细胞焦亡。
Nat Immunol. 2020 Jul;21(7):736-745. doi: 10.1038/s41590-020-0669-6. Epub 2020 May 4.
4
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.一种 SARS-CoV-2 蛋白相互作用图谱揭示了药物再利用的靶标。
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
5
Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.严重急性呼吸综合征冠状病毒2对干扰素表达的弱诱导作用支持了干扰素λ治疗早期2019冠状病毒病的临床试验。
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
6
Incidence of thrombotic complications in critically ill ICU patients with COVID-19.COVID-19 重症监护病房危重症患者的血栓并发症发生率。
Thromb Res. 2020 Jul;191:145-147. doi: 10.1016/j.thromres.2020.04.013. Epub 2020 Apr 10.
7
COVID-19 and emerging viral infections: The case for interferon lambda.新型冠状病毒肺炎与新发病毒性传染病：干扰素 λ的作用。
J Exp Med. 2020 May 4;217(5). doi: 10.1084/jem.20200653.
8
Type 1 interferons as a potential treatment against COVID-19.1 型干扰素作为一种对抗 COVID-19 的潜在治疗方法。
Antiviral Res. 2020 Jun;178:104791. doi: 10.1016/j.antiviral.2020.104791. Epub 2020 Apr 7.
9
COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?新型冠状病毒肺炎与非甾体抗炎药和皮质类固醇治疗：我们是否应在临床环境中限制其使用？
Ecancermedicalscience. 2020 Mar 30;14:1023. doi: 10.3332/ecancer.2020.1023. eCollection 2020.
10
Clinical and immunological features of severe and moderate coronavirus disease 2019.新型冠状病毒病 2019 重症和中度患者的临床和免疫学特征。
J Clin Invest. 2020 May 1;130(5):2620-2629. doi: 10.1172/JCI137244.
Zotero 插件